Revolution Medicines To Provide Update On RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program On July 15, 2024 In Investor Webcast

Author: Benzinga Newsdesk | July 08, 2024 04:09pm

Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard Medical School, and director of the Gastrointestinal Cancer Center and Robert T. & Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

Posted In: RVMD